Analysis of the inhibition of liver fibrosis by interferon beta administratio
Not Applicable
- Conditions
- chronic hepatitis and liver cirrhosis type C
- Registration Number
- JPRN-UMIN000005746
- Lead Sponsor
- Center for genomic medicine, Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. HIV infection 2. the patients who were performed liver transplantation 3. decompensated liver cirrhosis 4. autoimmuno hepatitis, alcoholic liver injury 5. pancytepenia (neutrophil<1500mm3, platelet<50000mm3, Hb<8g/dl) 6. autoimmuno disease and collagen disease 7. severe complication; renal disorder, severe diabates, pulmonary fibrosis, retinal hemorrhage 8. allergy for vaccination 9. allergy for drug and food 10. psychological disorder for example, depression 11. the patients who are not suitable for entry in this study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of the grade of liver fibrosis and biological marker for liver fibrosis (albmine, prothrombin time)
- Secondary Outcome Measures
Name Time Method